39541-91-8Relevant academic research and scientific papers
IMIDAZOPYRIDAZINE KINASE INHIBITORS USEFUL TO TREATING A DISEASE OR DISORDER MEDIATED BY AAK1, SUCH AS ALZHEIMER'S DISEASE, BIPOLAR DISORDER, PAIN, SCHIZOPHRENIA
-
Page/Page column 32-33, (2015/03/13)
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION
-
Page/Page column 95, (2012/06/30)
The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, R1a, R1b, R2, R3, R4a and R4b are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
A novel and efficient one pot synthesis of 2,4-disubstituted thiazoles and oxazoles using phenyltrimethylammoniumtribromide in ionic liquid
Muthyala, Manoj Kumar,Kumar, Anil
, p. 959 - 964 (2012/10/29)
A novel and efficient one-pot procedure has been described for synthesis of 2,4-disubstituted thiazoles and oxazoles from substituted ketones using phenyltrimethylammoniumtribromide as in situ brominating agent followed by reaction with thioamide/thiourea and amides/ureas, respectively in [bmim][BF4] ionicliquid. The advantages of the procedure include avoiding the handling of lacrymetric compounds, hazardous and toxic organic solvents along with good to excellent yield of the products.
3-AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS
-
Page/Page column 29-30, (2009/08/16)
The present invention relates to 3-azabicyclo[3.1.0]hexane derivatives, which are useful as vanilloid receptor (VR) ligands, methods of treating diseases, conditions and/or disorders modulated by vanilloid receptors with them, and processes for preparing them.
Fructose 1,6-bisphosphatase inhibitors
-
, (2008/06/13)
The present invention relates to certain quinazoline compounds which have utility in the treatment of diabetes mellitus, hypercholesterolemia, hyperlipidemia, diabetic complications and cancer. The invention also relates to pharmaceutical compositions and
Anilinoquinazoline inhibitors of fructose 1,6-bisphosphatase bind at a novel allosteric site: Synthesis, in vitro characterization, and x-ray crystallography
Wright, Stephen W.,Carlo, Anthony A.,Carty, Maynard D.,Danley, Dennis E.,Hageman, David L.,Karam, George A.,Levy, Carolyn B.,Mansour, Mahmoud N.,Mathiowetz, Alan M.,McClure, Lester D.,Nestor, Nestor B.,McPherson, R. Kirk,Pandit, Jayvardhan,Pustilnik, Leslie R.,Schulte, Gayle K.,Soeller, Walter C.,Treadway, Judith L.,Wan, Ing-Kae,Bauer, Paul H.
, p. 3865 - 3877 (2007/10/03)
The synthesis and in vitro structure-activity relationships (SAR) of a novel series of anilinoquinazolines as allosteric inhibitors of fructose-1,6-bisphosphatase (F16Bpase) are reported. The compounds have a different SAR as inhibitors of F16Bpase than a
